Nanotechnological strategies for therapeutic targeting of tumor vasculature

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1209-1222

  Ding, Yanping ^a   Li, Suping ^a   Nie, Guangjun ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

nanoparticle; neovascularization; therapy; tumor; vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CISPLATIN; DENDRIMER; DOXORUBICIN; FERRITIN; GOLD NANOPARTICLE; LIPOSOME; NANOPARTICLE; PACLITAXEL; POLYMER; QUANTUM DOT; SILVER NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS DERIVED NANOCARRIER;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; METASTASIS INHIBITION; MICELLE; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

EID: 84879681729     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.106     Document Type: Review

References (84)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996). (Pubitemid 26272076)
2. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7(11), 1194-1201 (2001). (Pubitemid 33063774)
3. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156(2), 361-381 (2000). (Pubitemid 30648785)
4. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410 (2003). (Pubitemid 37328844)
6. Hollebecque A, Massard C, Soria JC. Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr. Opin. Oncol. 24(3), 305-315 (2012).
7. Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vasc. Cell 3(1), 3 (2011).
8. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10(7), 505-514 (2010).
9. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100(6), 865-869 (2009).
10. Nolan DJ, Ciarrocchi A, Mellick AS et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21(12), 1546-1558 (2007). (Pubitemid 46955726)
11. Purhonen S, Palm J, Rossi D et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105(18), 6620-6625 (2008). (Pubitemid 351754556)
12. Feldman A, Restifo N, Alexander H et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 60(6), 1503-1506 (2000). (Pubitemid 30183414)
13. Muzykantov V, Radhakrishnan R, Eckmann D. Dynamic factors controlling targeting nanocarriers to vascular endothelium. Curr. Drug Metab. 13(1), 70-81 (2012).
14. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100(6), 865-869 (2009).
15. Brizel DM, Klitzman B, Cook M et al. A comparison of tumor and normal tissue microvascular hematocrits and red cell fluxes in a rat window chamber model. Int. J. Radiat. Oncol. Biol. Phys. 25(2), 269-276 (1993). (Pubitemid 23048779)
16. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26(1), 235-243 (2009).
17. Sharan M, Popel AS. A two-phase model for flow of blood in narrow tubes with increased effective viscosity near the wall. Biorheology 38(5-6), 415-428 (2001). (Pubitemid 34451112)
18. Calderon AJ, Muzykantov V, Muro S, Eckmann DM. Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology 46(4), 323-341 (2009).
19. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001). (Pubitemid 32476118)
20. Smith BR, Cheng Z, De A, Koh AL, Sinclair R, Gambhir SS. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 8(9), 2599-2606 (2008).
21. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007). (Pubitemid 350223348)
22. Lanza GM. ICAM-1 and nanomedicine: nature's doorway to the extravascular tissue realm. Arterioscler. Thromb. Vasc. Biol. 32(5), 1070-1071 (2012).
23. Decuzzi P, Lee S, Bhushan B, Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 33(2), 179-190 (2005). (Pubitemid 40509493)
24. Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27(30), 5307-5314 (2006). (Pubitemid 44080296)
25. Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp. Biol. Med. 236(1), 20-29 (2011).
26. Shah S, Liu Y, Hu W, Gao J. Modeling particle shape-dependent dynamics in nanomedicine. J. Nanosci. Nanotechnol. 11(2), 919-928 (2011).
27. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 26(1), 244-249 (2009).
28. Liu Z, Cai W, He L et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2(1), 47-52 (2007). (Pubitemid 46210038)
29. Park JH, Maltzahn GV, Zhang L et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20(9), 1630-1635 (2008).
30. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255 (2007). (Pubitemid 46739812)
31. Smith BR, Kempen P, Bouley D et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano. Lett. 12(7), 3369-3377 (2012).
32. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 14(2), 282-295 (2012).
33. Rodolfo M, Catò EM, Soldati S et al. Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther. 8(7), 491-496 (2001). (Pubitemid 32737835)
34. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J. Steroid Biochem. Mol. Biol. 111(1-2), 101-110 (2008).
35. Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol. Biol. 624, 375-384 (2010).
36. Huang S, Shao K, Liu Y et al. Tumor-targeting and microenvironment- responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7(3), 2860-2871 (2013).
37. Meng H, Xing G, Sun B et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 4(5), 2773-2783 (2010).
38. Lanza GM, Winter PM, Caruthers SD et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 13(2), 189-202 (2010).
39. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 107(8), 3027-3033 (2006).
40. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. Trans. 32(Pt 3), 397-402 (2004). (Pubitemid 38813523)
41. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8(8), 604-617 (2008).
42. Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296(5577), 2404-2407 (2002). (Pubitemid 34734217)
43. Xie J, Shen Z, Li KC, Danthi N. Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle. Int. J. Nanomedicine 2(3), 479-485 (2007). (Pubitemid 350047790)
44. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin. Cancer Res. 15(23), 7299-7308 (2009).
45. Danhier F, Vroman B, Lecouturier N et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J. Control Release 140(2), 166-173 (2009).
46. Dubey PK, Singodia D, Verma RK, Vyas SP. RGD modified albumin nanospheres for tumour vasculature targeting. J. Pharm. Pharmacol. 63(1), 33-40 (2011).
47. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 8(1), 250-259 (2011).
48. Yang X, Hong H, Grailer JJ et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32(17), 4151-4160 (2011).
49. Xie H, Diagaradjane P, Deorukhkar AA et al. Integrin alphavbeta3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int. J. Nanomedicine 6, 259-269 (2011).
50. Wang Z, Chui WK, Ho PC. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res. 28(3), 585-596 (2011).
51. Murphy EA, Majeti BK, Barnes LA et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105(27), 9343-9348 (2008).
52. Ho DN, Kohler N, Sigdel A et al. Penetration of endothelial cell coated multicellular tumor spheroids by iron oxide nanoparticles. Theranostics 2(1), 66-75 (2012).
53. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell. Biol. 163(4), 871-878 (2003). (Pubitemid 37517893)
54. Winer I, Wang S, Lee YE et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 70(21), 8674-8683 (2010).
55. Prickett WM, Van Rite BD, Resasco DE, Harrison RG. Vascular targeted single-walled carbon nanotubes for near-infrared light therapy of cancer. Nanotechnology 22(45), 455101 (2011).
56. Hu Q, Gu G, Liu Z et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials 34(4), 1135-1145 (2013).
57. Guo J, Gao X, Su L et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32(31), 8010-8020 (2011).
58. Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31(8), 2278-2292 (2010).
59. Deshayes S, Maurizot V, Clochard MC et al. "Click" conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis. Pharm. Res. 28(7), 1631-1642 (2011).
60. Curnis F, Arrigoni G, Sacchi A et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62(3), 867-874 (2002). (Pubitemid 34126966)
61. Pastorino F, Brignole C, Marimpietri D et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63(21), 7400-7409 (2003). (Pubitemid 37413482)
62. Murase Y, Asai T, Katanasaka Y et al. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy. Cancer Lett. 287(2), 165-171 (2010).
63. Zhang D, Feng X, Henning T et al. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 70(1), 180-189 (2009).
64. Hong H, Yang K, Zhang Y et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 6(3), 2361-2370 (2012).
65. Hong H, Zhang Y, Engle JW et al. In vivo targeting and positron emission tomography imaging of tumor vasculature with 66Ga-labeled nano-graphene. Biomaterials 33(16), 4147-4156 (2012).
66. Ruggiero A, Villa CH, Holland JP et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomedicine 5, 783-802 (2010).
67. Jubeli E, Moine L, Nicolas V, Barratt G. Preparation of E-selectin-targeting nanoparticles and preliminary in vitro evaluation. Int. J. Pharm. 426(1-2), 291-301 (2012).
68. Mann AP, Bhavane RC, Somasunderam A et al. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2(4), 298-304 (2011).
69. Kondo M, Asai T, Katanasaka Y et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 108(2), 301-306 (2004). (Pubitemid 37541787)
70. Chang DK, Chiu CY, Kuo SY et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 284(19), 12905-12916 (2009).
71. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12), 2491-2499 (2004). (Pubitemid 38715753)
72. Baguley BC, Ching LM. DMXAA: an antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys. 54(5), 1503-1511 (2002). (Pubitemid 35380056)
73. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31(27), 7115-7123 (2010).
74. Ngwa W, Makrigiorgos GM, Berbeco RI. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement. Phys. Med. Biol. 55(21), 6533-6548 (2010).
75. Philipp J, Dienst A, Unruh M et al. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. Arterioscler. Thromb. Vasc. Biol. 23(5), 905-910 (2003). (Pubitemid 36566185)
76. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 3(1), 27-34 (2002). (Pubitemid 34121143)
77. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275(5299), 547-550 (1997). (Pubitemid 27051913)
78. Dienst A, Grunow A, Unruh M. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl Cancer Inst. 97(10), 733-747 (2005). (Pubitemid 40872380)
79. Liu C, Huang H, Donate F et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 62(19), 5470-5475 (2002).
80. Bieker R, Kessler T, Schwöppe C et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 113(20), 5019-5027 (2009).
81. Agemy L, Sugahara KN, Kotamraju VR et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116(15), 2847-2856 (2010).
82. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
83. Wang H, Zhao Y, Wu Y et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32(32), 8281-8290 (2011).
84. Wang H, Wu Y, Zhao R, Nie G. Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv. Mater. 25(11), 1616-1622 (2013).